Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Enzon Pharmaceuticals has reported new preclinical data showing that treatment with PEG-SN38, Enzon's PEGylated SN38 compound, resulted in excellent antitumor activity in xenograft models of non-Hodgkin's lymphoma.
Subscribe to our email newsletter
Data from this study demonstrated that EZN-2208 treatment given as a single dose or in multiple dose regimen can cure animals bearing human non-Hodgkin’s lymphoma. EZN-2208 treatment cured animals and outperformed CPT-11, in very aggressive and advance disease preclinical models.
SN38 is the active metabolite of the widely used cancer drug CPT-11, marketed as Camptosar in the US.
Jeffrey Buchalter, chairman and CEO of Enzon, said: “The data further demonstrated the novel characteristics of our pegylated form of SN38, as this type of response by this class of drugs in NHL models is not expected.”